Onkológia 3/2017

Advanced urothelial carcinoma systemic treatment in the light of immunotherapy

This review is dedicated to the options of advanced urothelial cancer systemic treatment. In the first part, the author deals with the current standard approaches consisting of a platinum derivative in combination with gemcitabine as first-line and in particular vinflunine in second-line treatment. The second section stresses the importance of the immune system activation and of check-point inhibitor mechanisms in the treatment of malignant tumor diseases. The last part presents an overview of the clinical trials results with atezolizumab, pembrolizumab, nivolumab, and durvalumab, that will gradually find its place in the management of advanced urothelial carcinoma.

Keywords: advanced urothelial carcinoma, chemotherapy, immunotherapy, check-point inhibitors